Evidence map›Paper›PMID 41234988›Full record

ArticleCureus2025

Late-Onset Huntington's Disease in Mexico: A Retrospective Study.

Adriana Ochoa-Morales, Kerstin Beutelspacher-Fernandez, Aurelio Jara-Prado, Petra Yescas-Gómez, Jorge Luis Guerrero-Camacho, Nelva Jacquelinne Pérez-Pacheco, David Dávila-Ortiz de Montellano, Miguel Ángel Ramírez-García

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adriana Ochoa-MoralesGenetics Department, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Mexico City, MEX.
Kerstin Beutelspacher-FernandezGenetics Department, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Mexico City, MEX.
Aurelio Jara-PradoGenetics Department, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Mexico City, MEX.
Petra Yescas-GómezGenetics Department, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Mexico City, MEX.
Jorge Luis Guerrero-CamachoGenetics Department, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Mexico City, MEX.
Nelva Jacquelinne Pérez-PachecoGenetics Department, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Mexico City, MEX.
David Dávila-Ortiz de MontellanoGenetics Department, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Mexico City, MEX.
Miguel Ángel Ramírez-GarcíaGenetics Department, National Institute of Neurology and Neurosurgery Manuel Velasco Suárez, Mexico City, MEX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder. It typically presents between the ages of 30 and 40 years. However, a small proportion of cases begin after the age of 60 years, which is referred to as late-onset Huntington's disease (LoHD). This study aimed to describe the main characteristics of LoHD patients identified at Mexico's leading neurological center. Methodology A retrospective, cross-sectional study was conducted by reviewing records from 1994 to mid-2024. The data collected included the patients' age, age at onset, diagnostic delay time, family history, molecular outcomes, clinical manifestations at onset, and total motor scores on the Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS). Results From 1994 to mid-2024, the National Institute of Neurology and Neurosurgery Manuel Velasco Suárez reported 1,476 individuals with confirmed HD. Of those, 104 (7%) had LoHD, and 56.7% were female. The mean age of onset was 65.1 years. The mean age at molecular confirmation was 71.01 years. The mean diagnostic delay was 6.2 years. The origin of transmission was unknown in 41.3% of cases. Molecular testing revealed an average of 41.4 cytosine-adenine-guanine (CAG) repeats in the expanded allele. Motor symptoms were present at the beginning of the disease in 89% of cases. UHDRS-TMS showed a median score of 29. Conclusions LoHD is a rare form of HD with variable manifestations. A common finding in LoHD is the high proportion of patients with no family history of the disease. The lengths of the CAG expanded alleles are typically between 40 and 41 repeats. However, these lengths have also been observed in typical HD presentations. This suggests that further research is needed to identify possible modifiers and understand the pathways that delay disease onset.

Indexed as

frequency of diseasehuntington’s choreahuntington’s disease (hd)late-onsetmexico

Identifiers

PMID41234988
PMCPMC12610002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.